 |
|
|
New hormone therapy may fight resistant prostate cancerThe problem is that there are castration-resistant prostate cancer forms. Though the treatment kills some cancer cells, others remain alive but dormant, the researchers explained. And these cells can re-grow and survive without as much testosterone, thus becoming castration-resistant. Recent preliminary research suggests that a new hormone treatment could be a weapon for doctors in the battle against a form of prostate cancer that's resistant to surgical removal of the testicles. Only two of the three phases of research required for new drug treatments have been completed, however. At this point, it's not clear whether the treatment will go on to receive federal approval. The hormone treatment, called MDV3100, is being tested as a treatment for a disease known as castration-resistant prostate cancer, according to a report on the research, published online April 14 in The Lancet. According to researchers, encouraging anti-tumor activity with MDV3100 in patients with castration-resistant has been recorded before and after prostate cancer chemotherapy. They have begun a third phase of testing in which they will compare the hormone treatment to a placebo to see if it helps men with advanced prostate cancer live longer. NOTE: Issues on this site regarding prostate cancer and treatment options, are provided for information only, and are not meant to substitute for the advice of your own physician or other medical professional. Prostate-Report.org does not endorse any specific product, service or treatment. |
|